Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of helicobacter pylori: A randomized trial

American Journal of Gastroenterology

Volumn 111, Issue 3, 2016, Pages 381-387

  Liou, Jyh Ming ^a   Bair, Ming Jong ^b,c   Chen, Chieh Chang ^a   Lee, Yi Chia ^a   Chen, Mei Jyh ^a   Chen, Chien Chuan ^a   Tseng, Cheng Hao ^d   Fang, Yu Jen ^a   Lee, Ji Yuh ^a   Yang, Tsung Hua ^a   Luo, Jiing Chyuan ^e   Wu, Jeng Yih ^f   Chang, Wen Hsiung ^b   Chang, Chun Chao ^g   Chen, Chi Yi ^h   Chen, Po Yueh ^h   Shun, Chia Tung ^a   Hsu, Wen Feng ^a   Hung, Hsu Wei ⁱ   Lin, Jaw Town ^a,j   Chang, Chi Yang ^c   Wu, Ming Shiang ^a   more..

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c MEIHO UNIVERSITY   (Taiwan)

^d I SHOU UNIVERSITY   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^g TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^h CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

ⁱ Taipei Institute of Pathology   (Taiwan)

^j FU JEN CATHOLIC UNIVERSITY   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; UREA C 13; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ADULT; AGAR DILUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BLOATING; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; GENETIC POLYMORPHISM; HEADACHE; HELICOBACTER INFECTION; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PARALLEL DESIGN; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TAIWAN; TASTE DISORDER; TREATMENT OUTCOME; UREA BREATH TEST; VOMITING; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG MONITORING; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; ISOLATION AND PURIFICATION; MICROBIOLOGY; PROCEDURES; STOMACH DISEASES;

ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LANSOPRAZOLE; LEVOFLOXACIN; MALE; METRONIDAZOLE; MIDDLE AGED; STOMACH DISEASES; TREATMENT OUTCOME;

EID: 84962780431     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.439     Document Type: Article

References (27)

1. Ford AC, Forman D, Hunt RH, et al. H elicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomized controlled trials. BMJ 2014; 348: g3174.
2. Lee YC, Chen TH, Chiu HM, et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut 2013; 62: 676-82.
3. Chey WD, Wong BC. Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-25.
4. Gatta L, Vakil N, Vaira D, et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013; 347: f4587.
5. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014; 12: 177-86.
6. Malfertheiner P, Megraud F, O'morain C, et al. Management of Helicobacter pylori infection-The Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-64.
7. Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34-42.
8. Liou JM, Chang CY, Chen MJ, et al. The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors-A nationwide study. PLoS One 2015; 10: e0124199.
9. Gisbert JP, Perez-Aisa A, Bermejo F, et al. Second-line therapy with levofloxacin after failure of treatment to eradicate Helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients. J Clin Gastroenterol 2013; 47: 130-5.
10. Liou JM, Lin JT, Chang CY, et al. Levofloxacin-based and clarithromycinbased triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design. Gut 2010; 59: 572-8.
11. Liou JM, Chen CC, Chen MJ, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013; 381: 205-13.
12. Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011; 378: 507-14.
13. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard tripledrug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007; 146: 556-63.
14. Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M, et al. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2010; 31: 1077-84.
15. Ozdil K, Calhan T, Sahin A, et al. Levofloxacin based sequential and triple therapy compared with standard plus probiotic combination for Helicobacter pylori eradication. Hepatogastroenterology 2011; 58: 1148-52.
16. Qian J, Ye F, Zhang J, et al. Levofloxacin-containing triple and sequential therapy or standard sequential therapy as the first line treatment for Helicobacter pylori eradication in China. Helicobacter 2012; 17: 478-85.
17. Liou JM, Chen CC, Chen MJ, et al. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 2011; 66: 1847-52.
18. Camargo MC, Garca A, Riquelme A, et al. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol 2014; 109: 485-95.
19. Wu JY, Liou JM, Graham DY. Evidence-based recommendations for successful Helicobacter pylori treatment. Expert Rev Gastroenterol Hepatol 2014; 8: 21-8.
20. Liou JM, Chen CC, Chang CY, et al. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 2013; 68: 450-6.
21. Liou JM, Chang CY, Sheng WH, et al. Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin-and clarithromycin-based therapies. Antimicrob Agents Chemother 2011; 55: 1123-9.
22. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007; 12: 275-8.
23. Romano M, Cuomo A, Gravina AG, et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut 2010; 59: 1465-70.
24. Federico A, Nardone G, Gravina AG, et al. Efficacy of 5-day levofloxacincontaining concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology 2012; 143: 55-61.
25. Graham DY. Helicobacter pylori eradication therapy research: Ethical issues and description of results. Clin Gastroenterol Hepatol 2010; 8: 1032-6.
26. Liou JM, Chen CC, Chang CY, et al. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial. Gut; advance online publication, 3 September 2015. pii: gutjnl-2015-310142; doi:10.1136/gutjnl-2015-310142 [e-pub ahead of print].
27. Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377: 905-13.